Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Iadademstat by Oryzon Genomics for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia): Likelihood of Approval
Iadademstat is under clinical development by Oryzon Genomics and currently in Phase I for Acute Myelocytic Leukemia (AML, Acute Myeloblastic...
Data Insights
Vafidemstat by Oryzon Genomics for Borderline Personality Disorder (BPD): Likelihood of Approval
Vafidemstat is under clinical development by Oryzon Genomics and currently in Phase II for Borderline Personality Disorder (BPD). According to...